Committed to Quality
We focus on the development of revolutionary new products through integrating academic R&D capabilities, unmet clinical needs and industry resources. To accelerate commercialization and increase market share through selecting the proper strategic alliances is also the aim within our missions.
We mainly deliver medical devices to reduce the waste of medical manpower, to increase precision medicine and to provide telemedicine care in the spirit of seeking truth from facts.
3 million new cases per year in developed countries.
Acute upper gastrointestinal (UGI) bleeding is a potentially life-threatening abdominal emergency that remains a common cause of emergency admission. The UGI bleeding has 1/1000 incidence rate, which is about 6 million new cases occur each year globally, including 3 million new cases in developed countries. The statistic result shows that UGI bleeding has 3-8% mortality rate. In 2012, the median medical expense per case in USA was $6700 while the total medical expense was around $3.8 billion.
Upper GI rebleeding hard to find in time.
After an emergent treatment on acute UGI bleeding, rebleeding could still occur. The rebleeding rate on the median-risk level patients is 12% and can be as high as 38% on the high-risk level patients. Most of rebleeding happens within the first 72 hours after treatment. Thus, patients at both median-risk and high-risk level are asked to take a monitoring procedure during their admission. However, the current monitoring method, i.e. measuring body temperature, pulse rate, respiration rate, and blood pressure, cannot clearly indicate whether or not the rebleeding occurs before blood loss is more than 15% of the total blood volume (around 750-1500 cc blood loss). However, this amount of blood loss could already lead to complications, huge blood transfusion, or operation.
Real-time UGI rebleeding monitoring system
In order to provide real-time UGI rebleeding detection, we have invented an image based UGI monitoring system. The system consists of a tiny endoscope, a wearable host device, and a mobile display device. The tiny endoscope connect with the host and placed at stomach via nasal tunnel. The host is used to acquire image regularly and send to the mobile device for image analysis. An algorithm built in the mobile device is able to automatically judge whether rebleeding occurs.
Advantages of this monitoring system are (1) efficient and direct monitoring UGI tract, (2) less manpower on regular checking the patient’s condition, and (3) reduce health care expenses.
EARLY & SENSITIVE
SAVE MANPOWER FOR
Dr. An received his Ph.D. in mechanical engineering and applied mechanics in 1975 from Lehigh University in Bethlehem, PA. In 1993 he was appointed Director of the Orthopedic Biomechanics Laboratory at the Mayo Clinic in Rochester, MN, and was named the John and Posy Krehbiel Professor of Orthopedics, Mayo Medical School. Dr. An has received several awards from various societies, including the You-Li Chou Medal from the Taiwanese Society of Biomechanics, the Borelli Award from the ASB, the Distinguished Alumnus Award from National Cheng-Kung University, the Neer Award from ASES, the Kappa Delta Award from AAOS, and was named as a Fellow of the ASME in 2007. Dr. An’s research interests include biomechanics, biomaterials, imaging, wheelchair propulsion, orthopedics, and rehabilitation. He is an emeritus professor of orthopedics and biomedical engineering, and emeritus consultant in the Department of Orthopedic Surgery at Mayo Clinic.
Dr. Weng received his Ph.D. in Engineering Science in NCKU, Taiwan. Now he works as an assisting researcher in Medical Device Innovation Center (MDIC), NCKU. His main research interests include medical device regulations, Nano-biotechnology, micro/nanofluidics and their biomedical applications. Besides, He is also responsible for establishing and maintaining the ISO 13485, ISO 14971 and ISO 62366 documents in MDIC. In 2017-2018, He implemented a Project “Strengthen the Post-market Management of Medical Devices” for TFDA. His major tasks in this project were to evaluate, construct, and connect industry capabilities through value-chain analysis. Through the experiences, he has gained a good reputation for medical device regulation.
CC received his Ph.D. degree from the Department of Neurology, University Hospital Zurich, Switzerland, and his master’s and bachelor’s degree in Department of Mechanical Engineering, NTU, Taiwan. Prior to MediVisionTech, CC involved in forefront innovation development among the engineering, neuroscience, and medical device fields for 11 years. This multidisciplinary experience gives CC an ability to integrate, cooperate and communicate with experts in various fields efficiently.
PF is an essential part of the team and has been with MediVisionTech since the very beginning. PF has an international trade background and was a secretary general in Medical Device Innovation Center, NCKU. Now, PF is responsible for financing, public relations, managing the funded projects and administrative affairs of the MediVisionTech.
Kevin received his Ph.D. degree from National Cheng Kung University, Taiwan, and his bachelor’s degree in Department of Biochemistry & Molecular Biology
University of California, Davis, US. Prior to MediVisionTech, Kevin participated in forefront innovation development of reagent development for a lysis free on-site screening platform and a Point-of-Care (POC) photonic qPCR device. These RD experiences have made Kevin an outstanding PM, being able to efficiently communicate with experts and strictly follow develop schedule.
Quality & regulatory specialist
Tina graduated from the English Department at Wenzao Ursuline College of Languages and has rich experience in international trade for more than 10 years. She also has the practical experience of regulatory affairs for almost 4 years and was responsible to apply Quality System Documentation (QSD) and importing license for importing European, USA, Japan, China & Nepal's ophthalmic medical equipment legally.
Dr. Chuang is an attending physician of the Department of Internal Medicine in NCKU Hospital and concurrently a clinical associate professor. He is the co-founder of MediVisionTech and is in charge of providing expert clinical advice and performing clinical trials.
Dr. Chiou received his Ph.D. in Finance from The City University of New York in New York City, NY. He is a Certified Public Accountant, Certified Management Accountant, Certified Fraud Examiner and Certified Fraud Examiner in the USA. He was a full professor of Accountancy and Finance at the NCKU. His academic work focuses on Corporate Finance, Investment, and Financial Accounting. Dr. Chiou had numerous leadership roles at NCKU in his career. He was the VP in Finance, CEO of NCKU Endowment Fund and Board Member of NCKU Venture Capital. He is also a current or past Independent Director, Supervisor, Audit Committee Member, and Remuneration Committee Member of public companies and SOEs.